Orotecan – Talk Bio

Actionable Insights Powered by AI

Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 days ago talkbio0Tagged AACR-NCI-EORTC, ARID1A mutation, Clinical Trials, Edison Oncology, Molecular Targets, Orotecan, ovarian neoplasm, OXPHOS pathway, Phase 1 - 2a, VAL-413

Edison Oncology; 2025 AACR-NCI-EORTC; Molecular Targets; Cancer Therapeutics; VAL-413; Orotecan; EO3001; ARID1A mutation; ovarian cancer; Phase 1-2a clinical trial; OXPHOS pathway